Improving the design and delivery of RNA therapies
Official title: Multidimensional approaches to understand and improve RNA therapeutic design and delivery
Funded at University of Michigan at Ann Arbor · NIH-11103184 · Data updated 2026-11-12
This study is looking at ways to improve how messenger RNA (mRNA) treatments are delivered in the body, which could lead to better therapies for patients in the future, especially after the success of COVID-19 vaccines.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | June 10, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $370,686 |
| NIH project number | 5R35GM154852-02 |
| Project ID | NIH-11103184 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who may benefit from RNA therapeutics, including those with conditions that could be treated with mRNA-based treatments.
✕Less likely to help
Patients who do not have conditions that could be addressed by RNA therapies may not receive any benefit from this research.
What this research studies
This research focuses on enhancing RNA therapeutics, particularly messenger RNA (mRNA) delivery systems, which have gained attention due to the success of COVID-19 vaccines. The project aims to understand how different factors, such as the properties of RNA and its delivery vehicles, affect their effectiveness in the body. By using advanced techniques to study these interactions, the researchers hope to develop better RNA therapies that can be used in various medical applications. Patients may benefit from improved treatments that utilize these innovative RNA delivery systems.
Why it matters
Potential benefit: If successful, this research could lead to more effective RNA-based therapies for a range of diseases.
How similar studies have gone: Other research has shown promise in RNA therapeutic delivery systems, particularly with the recent success of mRNA vaccines, indicating that this approach has potential.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Wu, Connie — University of Michigan at Ann Arbor
- Study coordinator: Wu, Connie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.